Canaccord lowered the firm’s price target on 10x Genomics (TXG) to $18 from $20 and keeps a Buy rating on the shares. The firm said theirlower target is driven by lower estimates due to near-term uncertainty. They remain optimistic, recognizing potential headwinds related to academic funding are relatively alarming and the company’s commercial reorganization will take time.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics downgraded to Market Perform from Outperform at Leerink
- 10x Genomics Reports 2024 Earnings and 2025 Outlook
- Balanced Outlook Amid Revenue Growth and Market Risks: Hold Rating for 10x Genomics
- 10x Genomics reports Q4 EPS (40c), consensus (11c)
- 10x Genomics sees 2025 revenue $610M-$630M, consensus $630.36M